BusinessCrownBio Launches New Humanized Target Model for ImmunotherapyBy Nasdaq OMXApr 26, 2018, 12:00 PM UTC
BusinesseFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal ChemistryBy Nasdaq OMXApr 26, 2018, 11:31 AM UTC
BusinessIntrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering ConferenceBy Nasdaq OMXApr 24, 2018, 1:27 PM UTC
BusinessVBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) PatientsBy Nasdaq OMXApr 17, 2018, 12:01 PM UTC
BusinessInnovest Global Inc. Q1 Financials Beat Revenue Estimates, $600K+ Cash on Hand, and Cancelled 50 Million of its Outstanding SharesBy Nasdaq OMXApr 16, 2018, 7:02 PM UTC
BusinesseFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual MeetingBy Nasdaq OMXApr 16, 2018, 12:01 PM UTC
BusinessFluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical ResearchBy Nasdaq OMXApr 13, 2018, 8:10 PM UTC
BusinessINmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, PhD, Delivers Keynote at CTERP International ConferenceBy Nasdaq OMXApr 12, 2018, 2:05 PM UTC
